Healthcare News
Market coverage tagged Healthcare.
- Market Flux Event
FDA Approves Eli Lilly Onswik as First Once-Weekly Basal Insulin for Type 2 Diabetes
The U.S. Food and Drug Administration approved Eli Lilly's Onswik, generic name insulin efsitora alfa-gobe, as a once-weekly basal insulin injection for adults living with type 2 diabetes…
- Market Flux Event
FDA Plans to Overhaul Tobacco Product Review Process to Speed Vape and Nicotine Pouch Approvals
The U.S. Food and Drug Administration is expected to announce in the coming days that it will revisit a 2021 rule governing new tobacco product applications, according to people familiar…
- Most Active
Viking Therapeutics VK2735 Retains Up to 97% of Weight Loss With Reduced Dosing, Stock Surges 30% Plus
Viking Therapeutics reported positive topline results from a maintenance study of its dual GLP-1/GIP agonist VK2735, showing the drug held up to 97% of prior weight loss when patients…
- Most Active
Celldex CLDX Stock Drops 28% as Phase 3 Barzolvolimab Hives Data Triggers Sell-the-News Reaction Despite Trial Success
Celldex Therapeutics reported positive top-line results Tuesday from its two pivotal Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 studies of barzolvolimab in adults with chronic spontaneous…
- Top Mover
CMS Proposes Up to 15% Medicare Lab Reimbursement Cuts Sending Quest Diagnostics and Labcorp Shares Lower
Quest Diagnostics fell roughly 5-7% in Tuesday trading after the Centers for Medicare and Medicaid Services disclosed it has been overpaying for lab work by approximately 16% compared to…
- Top Mover
CMS Proposes Up to 15% Medicare Reimbursement Cuts for Clinical Labs, Hitting Labcorp and Quest Hard
The Centers for Medicare and Medicaid Services released preliminary 2027 Clinical Laboratory Fee Schedule rates on September 22 proposing annual reimbursement cuts of up to 15% for…
- Top Mover
Amgen's Dazodalibep Hits Phase 3 Primary Endpoint in Sjogrens Disease Trial
Amgen reported positive top-line results from its Phase 3 OASIZ 301 trial of dazodalibep in patients with moderate-to-severe systemic Sjogren's disease, a chronic autoimmune condition that…
- Unusual Volume
Viking Therapeutics Surges Up to 36% After VK2735 Maintains 90-97% of Weight Loss at Reduced Dosing Frequencies
Viking Therapeutics reported positive topline results from a maintenance study of VK2735, its dual GLP-1/GIP receptor agonist, showing that patients who had lost roughly 16% to 19% of body…
- Most Active
Xenon Pharmaceuticals Plunges 30% After Pausing Azetukalner Enrollment in Phase 3 Depression Trials
Xenon Pharmaceuticals shares fell as much as 30% on Friday, their worst single-day decline since 2017, after the company voluntarily halted new enrollment in its Phase 3 studies of…
- Unusual Volume
Xenon Pharmaceuticals Shares Plunge 25% After Pausing Azetukalner Depression Trials on Adverse Events
Xenon Pharmaceuticals fell roughly 22 to 25 percent in premarket trading on September 18, 2026, after the company voluntarily paused new enrollment in its Phase 3 studies of azetukalner in…
- Market Flux Event
Healthcare Companies Converge on Morgan Stanley and Deutsche Bank Conferences With Growth Updates
A broad range of healthcare and biotech companies presented at two major industry gatherings on September 16, 2026: the Morgan Stanley 24th Annual Global Healthcare Conference and the…
- Market Flux Event
Dozens of Healthcare Companies Present at Morgan Stanley 24th Annual Global Healthcare Conference in New York
The Morgan Stanley 24th Annual Global Healthcare Conference, held in New York City on September 15-16, 2026, drew a broad cross-section of biotech, pharmaceutical, medtech, and digital…
- Most Active
Vera Therapeutics Surges Then Reverses After TRUTAKNA Phase 3 Trial Hits All Endpoints
Vera Therapeutics shares jumped as much as 14.8% in premarket trading on September 15 before reversing course to trade down about 2% at $33.34 by midday, after the company announced that…
- Market Flux Event
Vera Therapeutics Stock Falls Despite FDA Alignment on Accelerated Review Path for Atacicept
Vera Therapeutics shares slid on Tuesday even after the company announced the FDA had aligned on an accelerated review path for atacicept, its drug targeting IgA nephropathy, a serious…
- Market Flux Event
FDA Accepts Cogent Biosciences NDA for Bezuclastinib as Novo Nordisk Rebrands Amid Lilly Competition
Cogent Biosciences secured a key regulatory milestone as the FDA accepted its New Drug Application for bezuclastinib in patients with Advanced Systemic Mastocytosis, assigning a PDUFA…
- Market Flux Event
Biotech and Pharma Companies Highlight Launches, Pipelines and Rare Disease Markets at Morgan Stanley Healthcare Conference
More than a dozen biotechnology and pharmaceutical companies presented at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026, offering investors updates on…
- Market Flux Event
Dozens of Healthcare and Biotech Companies Showcase Pipelines and Launch Plans at Morgan Stanley, Jefferies and H.C. Wainwright Conferences
September 14, 2026 saw a broad wave of healthcare and biotech presentations across three major investor conferences, with the Morgan Stanley 24th Annual Global Healthcare Conference drawing…
- Market Flux Event
BioNTech Rises on Lung Cancer Data While Cullinan Falls as Sector Sees Broad Monday Premarket Gains
Healthcare stocks broadly rose in Monday premarket trading, with BioNTech leading the sector after presenting positive lung cancer pipeline data at the IASLC 2026 World Conference on Lung…
- Most Active
Opus Genetics Reports Vision Improvements at Low Dose in BEST1 Gene Therapy Trial, Stock Hits 52-Week High
Opus Genetics (Nasdaq: IRD) released three-month topline data from Cohort 1 of its Phase 1/2 BIRD-1 gene therapy trial on September 9, reporting that its OPGx-BEST1 therapy produced vision…
- Market Flux Event
Major Healthcare Conferences Draw Dozens of Companies With Pipeline Updates and Growth Strategies
September 9, 2026 became a showcase day for the healthcare sector as dozens of companies presented across three major investor conferences running simultaneously: the Wells Fargo 21st…
- Market Flux Event
Healthcare Conference Season Peaks With Dozens of Company Presentations as Biotech Names Draw Investor Scrutiny
Dozens of healthcare companies took the stage on September 9 at three major investor gatherings, the Wells Fargo 21st Annual Healthcare Conference, the Cantor Fitzgerald Global Healthcare…
- Top Mover
Amgen Plunges 10% as Novartis Lp(a) Trial Failure Casts Doubt on Olpasiran Program
Amgen shares fell roughly 10% on Tuesday, putting the stock on course for its worst single-day decline since 2000, after Novartis reported that its Lp(a)-lowering drug pelacarsen failed in…
- Market Flux Event
Novartis and Ionis Heart Drug Pelacarsen Fails Phase 3 Trial, Sending Shares Lower
Pelacarsen, a drug developed by Novartis and partner Ionis Pharmaceuticals to lower lipoprotein(a), or Lp(a), failed to reduce the risk of cardiovascular events in a late-stage clinical…
- Market Flux Event
FDA Grants Accelerated Approval to AstraZeneca's Breast Cancer Pill Etcamah for ESR1-Mutated Tumors
The U.S. Food and Drug Administration has granted accelerated approval to AstraZeneca's camizestrant, branded as Etcamah, for the treatment of hormone receptor-positive, HER2-negative…
- Most Active
Ultragenyx Shares Plunge 44% After Angelman Syndrome Drug Fails Late-Stage Trial
Ultragenyx Pharmaceutical shares cratered roughly 44% on September 3, 2026, after its experimental treatment for Angelman syndrome, a rare neurodevelopmental genetic disorder, failed to…
Show 25 more
- Unusual Volume
Novartis Jumps 6% After MS Pill Remibrutinib Succeeds in Two Phase 3 Trials, Even as CAR-T Deaths Trigger Pause
Novartis shares surged roughly 6% to approximately $161.10 on Tuesday, on track for their best single-day gain since 2023, after the company reported that remibrutinib, an oral BTK…
- Market Flux Event
FDA Expands Mounjaro Label to Reduce Heart Attack and Stroke Risk in Type 2 Diabetes Patients
The FDA approved an expanded label for Eli Lilly's Mounjaro (tirzepatide) to reduce major adverse cardiovascular events, including heart attack and stroke, in high-risk patients with type 2…
- Market Flux Event
BioNTech Halts Phase 2 mRNA Colorectal Cancer Trial After Safety Board Orders End, Shares Fall 10%
BioNTech terminated its mid-stage clinical trial of autogene cevumeran, its mRNA-based cancer vaccine for colorectal cancer, after the trial's independent Data Safety Monitoring Board…
- Market Flux Event
FDA Clears COVID Vaccines From Pfizer-BioNTech and Moderna for 2026-2027 Season as Priovant Wins Dermatomyositis Approval
The FDA delivered a cluster of drug approvals on August 27, 2026. Pfizer and BioNTech received approval for an updated XFG-adapted formulation of Comirnaty for the 2026-2027 COVID-19…
- Market Flux Event
FDA Approves Revolution Medicines Daraxonrasib as First RAS-Blocking Pill for Pancreatic Cancer
Revolution Medicines received FDA approval on August 26 for daraxonrasib, a once-daily oral drug designed to block multiple forms of the RAS protein in patients with previously treated…
- Most Active
Biomea Fusion Completes Enrollment in Phase II Diabetes Trial, Stock Surges Nearly 9%
Biomea Fusion shares jumped roughly 8.8% in premarket trading on August 24 after the company announced it had completed enrollment in COVALENT-211, its Phase II trial of icovamenib in…
- Most Active
Moderna Shares Whipsaw for Third Session After Phase 3 Cancer Vaccine Surge
Moderna shares have swung violently for three consecutive sessions following positive Phase 3 results for its personalized mRNA cancer vaccine, which triggered a roughly 177% single-session…
- Market Flux Event
FDA Clears 11 Higher-Nicotine ZYN Ultra Products for Philip Morris International
The U.S. Food and Drug Administration authorized 11 ZYN Ultra nicotine pouch products for Philip Morris International on August 21, 2026, clearing a new line of pouches with higher nicotine…
- Market Flux Event
Moderna Surges Over 140% After Merck mRNA Cancer Vaccine Scores Historic Phase 3 Win
Moderna shares rocketed more than 140% and Merck gained roughly 12% on August 19 after the two companies reported the first-ever positive Phase 3 result for an individualized mRNA cancer…
- Most Active
Moderna Sheds Up to 25% and 18 Billion in Market Cap as Investors Pocket Gains From Historic Cancer Vaccine Surge
Moderna shares fell as much as 25% on Thursday, erasing roughly 18 billion dollars in market value after closing Wednesday up 176.9% on breakthrough Phase 3 cancer vaccine trial results…
- Market Flux Event
Moderna Erases $18 Billion in Market Value the Day After Its Historic 177% Cancer Vaccine Surge
Moderna shares fell as much as 25% on Thursday, wiping out roughly $18 billion in market value, one day after the stock posted a 177% gain, its best single session ever, on breakthrough…
- Unusual Volume
Moderna Sheds Up to 25% in Profit-Taking Selloff After Historic 177% Cancer Vaccine Surge
Moderna shares fell as much as 25% on Thursday, erasing roughly $18 billion in market value after the stock's record single-day gain of 176.9% on Wednesday. The rally had been driven by…
- Market Flux Event
Moderna and Merck Melanoma Vaccine Hits Phase 3 Goals in Historic mRNA Cancer Trial
Moderna and Merck announced Wednesday that their personalized mRNA cancer vaccine, called intismeran autogene, met its primary endpoints in a Phase 3 trial targeting high-risk melanoma…
- Market Flux Event
Ultragenyx Gets Accelerated FDA Approval for DTX401 Gene Therapy Targeting Rare Metabolic Disorder GSDIa
The U.S. Food and Drug Administration granted accelerated approval to Ultragenyx Pharmaceutical's gene therapy DTX401, known generically as pariglasgene brecaparvovec, for the treatment of…
- Most Active
Moderna Surges 177% After mRNA Melanoma Vaccine Succeeds in First-Ever Phase 3 Cancer Vaccine Trial
Moderna shares closed up 177% on Wednesday, their best single day on record, adding roughly $44 billion in market cap after the company and partner Merck announced positive topline results…
- Top Mover
Eli Lilly Hits All-Time High as Stock Surges 4% and Deal With Amplitude Expands RNA Vaccine Pipeline
Eli Lilly shares climbed 4.0% on August 19, 2026, reaching a record intraday high of $1,249.95 as a broad biopharma rally, triggered by Moderna's cancer-vaccine breakthrough, lifted the…
- Top Mover
Merck and Moderna Phase 3 mRNA Cancer Vaccine Win Lifts Pfizer Stock While Raising Competitive Stakes
Pfizer shares rose about 1% to $27.50 on Wednesday, August 19, bringing the stock's year-to-date gain to roughly 15%, as broad enthusiasm over a landmark cancer vaccine trial lifted the…
- Top Mover
Merck Hits Best Single-Day Gain Since 2009 After Phase 3 Melanoma Vaccine Trial Success With Moderna
Merck surged more than 12% on August 19, its best intraday gain since 2009, after the company and Moderna reported positive topline results from the Phase 3 INTerpath-001 trial of their…
- Top Mover
Moderna Surges 177% in Best Day Ever After mRNA Cancer Vaccine Succeeds in Phase 3 Trial
Moderna shares soared 177% on Wednesday, their best single-day gain on record, adding roughly $44 billion in market cap and lifting the stock from a prior close of $62.96 to as high as the…
- Market Flux Event
Moderna Surges 125% After mRNA Cancer Vaccine Hits Phase 3 Goals in Melanoma Trial
Moderna shares more than doubled on Wednesday, rising roughly 125% to around $142, after the company and Merck announced that their personalized mRNA cancer vaccine intismeran met the…
- Top Story
Moderna and Merck Cancer Vaccine Hits Phase 3 Primary Goal in Melanoma Trial, Sending Moderna Stock Up More Than 100%
Moderna and Merck announced Wednesday that their personalized mRNA cancer vaccine, intismeran autogene, met both the primary endpoint of recurrence-free survival and the key secondary…
- Market Flux Event
Moderna Stock Nearly Doubles After Phase 3 Cancer Vaccine Trial Hits Key Endpoints
Moderna shares surged as much as 99% in premarket trading on Wednesday, touching $125.68 from Tuesday's close of $62.96, after the company and Merck announced positive topline results from…
- Unusual Volume
Moderna Surges Record 177% After Melanoma Vaccine Succeeds in Phase 3 Trial With Merck
Moderna and Merck reported positive topline results Wednesday from the Phase 3 INTerpath-001 trial of intismeran autogene, a personalized mRNA-based individualized neoantigen therapy…
- Market Flux Event
Moderna and Merck Cancer Vaccine Hits Phase 3 Primary Goal in Melanoma Trial, Sending Moderna Stock Up More Than 100%
Moderna and Merck announced Wednesday that their personalized mRNA cancer vaccine, intismeran autogene, met both the primary endpoint of recurrence-free survival and the key secondary…
- Most Active
Amylyx Pharmaceuticals Surges Over 50% After Avexitide Hits Primary Endpoint in Phase 3 LUCIDITY Trial
Amylyx Pharmaceuticals stock surged as much as 53% on August 18, hitting a 52-week high of $29.86, after the company reported positive topline results from its Phase 3 LUCIDITY clinical…